Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Non-Current Deferred Tax Liability (2022 - 2024)

Sunshine Biopharma filings provide 3 years of Non-Current Deferred Tax Liability readings, the most recent being -$67.0 for Q4 2024.

  • On a quarterly basis, Non-Current Deferred Tax Liability changed N/A to -$67.0 in Q4 2024 year-over-year; TTM through Dec 2024 was -$67.0, a N/A change, with the full-year FY2024 number at -$67.0, changed N/A from a year prior.
  • Non-Current Deferred Tax Liability hit -$67.0 in Q4 2024 for Sunshine Biopharma, down from $48729.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $48729.0 in Q1 2024 to a low of -$67.0 in Q4 2024.
  • Median Non-Current Deferred Tax Liability over the past 3 years was $43032.0 (2022), compared with a mean of $39781.0.
  • The widest YoY moves for Non-Current Deferred Tax Liability: up 13.24% in 2024, down 13.24% in 2024.
  • Sunshine Biopharma's Non-Current Deferred Tax Liability stood at $43032.0 in 2022, then changed by 0.0% to $43032.0 in 2023, then plummeted by 100.16% to -$67.0 in 2024.
  • The last three reported values for Non-Current Deferred Tax Liability were -$67.0 (Q4 2024), $48729.0 (Q3 2024), and $48729.0 (Q2 2024) per Business Quant data.